Lucid picked up the award for Excellence in Rare Diseases and Orphan Drugs at this year’s PMEA Awards, which were hosted in London earlier this week.
The agency’s ‘EIDON’ project for AbbVie developed a specialist network and increased the number of specialist centres to advance outcomes of patients with hidradenitis suppurativa (HS).
PMEA’s judges said:
“The Eidon project took a whole programme approach, building awareness from zero to create a network and care delivery infrastructure.
“It is a clearly-structured entry with key behaviours and outcomes defined and measured, and most important, an impressive number of patients were treated.”
Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases.
Tags: Biologicals HUMIRA Rare Disease Treatment